Neuromyelitis optica in patients with increased interferon alpha concentrations

[1]  Bernhard Hemmer,et al.  Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders , 2019, The Lancet Neurology.

[2]  F. Paul,et al.  Apheresis therapies for NMOSD attacks , 2018, Neurology(R) neuroimmunology & neuroinflammation.

[3]  Y. Kawasawa,et al.  B-Cell-Intrinsic Type 1 Interferon Signaling Is Crucial for Loss of Tolerance and the Development of Autoreactive B Cells , 2018, Cell reports.

[4]  Anne-Kathrin Kienzler,et al.  Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica , 2018, Brain : a journal of neurology.

[5]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[6]  Y. Crow,et al.  Neuromyelitis optica in a child with Aicardi-GoutiÈres syndrome , 2015, Neurology.

[7]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[8]  B. Weinshenker,et al.  Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. , 2015, JAMA neurology.

[9]  K. Kyvik,et al.  Interferon Alpha Association with Neuromyelitis Optica , 2013, Clinical & developmental immunology.

[10]  Su-Hyun Kim,et al.  Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? , 2012, Multiple sclerosis.

[11]  A. Reder,et al.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis , 2012, Journal of the Neurological Sciences.

[12]  Jacqueline A Palace,et al.  Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. , 2010, Archives of neurology.

[13]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.